Jana Partners is playing for keeps with Cooper Companies (COO). If you've been watching the medtech space lately, you know the activist playbook usually starts with a polite letter and ends with a sledgehammer. Right now, the target is the strange, almost accidental marriage between high-volume contact lenses and specialized women’s health devices.
The logic is simple. Cooper runs two massive businesses—CooperVision and CooperSurgical—that share almost zero DNA. One sells daily disposables to teenagers and office workers; the other sells IVF equipment and IUDs to surgical clinics. Jana argues that keeping them under one roof isn't just inefficient; it’s actively suppressing the stock price. Honestly, they’re probably right.
Why Jana Partners wants a Cooper Companies breakup
Activists don't just show up for fun. They show up when they see a "conglomerate discount." Jana Partners, led by Scott Ostfeld, believes that if you liberated the vision business and the surgical business, the market would value them at a much higher multiple.
The centerpiece of this plan is a potential monster deal with Bausch + Lomb (BLCO). Jana has floated the idea of merging CooperVision with Bausch to create an undisputed titan in eye care. Brent Saunders, the CEO of Bausch + Lomb, hasn't exactly been shy about his interest. He’s on record saying he supports the idea because it would create a scaled competitor capable of going toe-to-toe with Johnson & Johnson.
Think about the math for a second. CooperVision controls about 25% of the U.S. contact lens market. Bausch is another heavy hitter. Smashing them together isn't just a "synergy" play; it’s a total takeover of the shelf space in every optometry office in America.
The surgical side is a hidden gem
While everyone talks about the lenses, the CooperSurgical piece is what really makes this a smart play. It’s the world's largest medical device fertility company. It’s high-margin, it’s growing, and it’s increasingly becoming a "FemTech" leader.
But here’s the problem. In its current form, CooperSurgical is basically the neglected middle child. Management’s attention is constantly pulled toward the high-volume, commodity-adjacent world of contact lenses. By spinning it off or selling it to a dedicated healthcare player, you’d likely see its valuation skyrocket. Fertility is a massive growth sector, yet it’s currently buried in a balance sheet dominated by silicone hydrogel.
Breaking down the 2026 outlook
Management isn't just sitting around waiting for the axe to fall. In December 2025, they initiated a formal strategic review. That was a direct white flag to Jana and fellow activist Browning West. They’ve already started a major reorganization, taking an $89 million charge to save about $50 million annually starting this year.
The numbers for 2026 look decent on the surface.
- Revenue Guidance: $4.30 billion to $4.34 billion.
- Adjusted EPS: $4.45 to $4.60.
- Organic Growth: Aiming for mid-to-high single digits.
But "decent" isn't what Jana wants. They want the stock, which has hovered around $83 recently, to push toward the $100 mark. The gap between the current price and the sum-of-the-parts value is exactly where the profit lives. If the strategic review results in a spinoff or a sale of the vision unit, that $83 price point is going to look like a bargain in the rearview mirror.
What most investors get wrong about COO
Many people think of Cooper as a safe, boring "dividend-ish" stock. It’s not. It’s a battleground. You aren't just betting on how many people need contact lenses in 2026; you’re betting on whether Scott Ostfeld can force the board to pull the trigger on a divestiture.
The biggest risk? Regulatory pushback. A Cooper-Bausch merger would face intense scrutiny from the FTC. They don't exactly love it when two of the top three players in a market decide to become one. If that deal gets blocked, the "breakup" thesis loses its biggest catalyst.
However, even without the Bausch deal, a clean split into two pure-play companies—one for Vision, one for Surgical—removes the complexity that scares away many institutional investors. Simplicity sells.
Real-world moves for your portfolio
If you're holding COO or looking at an entry point, stop obsessing over the quarterly earnings beats. They’ll likely beat because they always set the bar low. Instead, watch the board appointments. Browning West has been pushing for four new directors. If those seats get filled by activist-friendly faces, the breakup becomes an "when," not an "if."
Keep a close eye on the debt-to-equity ratio, currently sitting around 0.30. Cooper has a clean balance sheet, which gives them the flexibility to do something dramatic—like a massive share buyback or a final "poison pill" acquisition to stave off the activists. But with Jana holding a significant stake, the momentum is firmly on the side of structural change.
The bottom line is that Cooper Companies as we know it probably won't exist by 2027. It's too fragmented for its own good. Whether it's a merger with Bausch or a two-way split, the "conglomerate" era of this firm is over.
To stay ahead, track the 13D filings from Jana Partners over the next few months to see if they're increasing their stake. If they cross the 5% threshold again or release another public letter, that's your signal that the heat is turning up. Monitor the progress of the "strategic review" mentions in their Q1 2026 earnings call on March 5. Any shift in language from "evaluating" to "executing" is your cue to re-evaluate your position.
